Skip to main content


Associate Professor
Naor Bar-Zeev

Departmental Affiliations

Global Disease Epidemiology and Control

Naor Bar-Zeev PhD, MBiostat, MPH, MBBS, is a pediatric infectious disease physician who studies how to maximize vaccine benefits for low-resource, high-mortality areas.

Contact Info

Research Interests

vaccines and immunization; maternal, infant and child health; non-specific effects; heterologous effects; epidemiology; clinical trials; low income countries; tropical medicine; Malawi; pneumococcal disease; rotavirus; RSV; health economics;
Experiences & Accomplishments
Charles Darwin University
University of Melbourne
University of Melbourne
Monash University
Dr Naor Bar-Zeev is a pediatric infectious diseases physician and statistical epidemiologist. His research interest is in understanding how to maximize the benefit of existing and future vaccines in low-resourced high mortality settings, how best to protect vulnerable groups like newborns and pregnant women and how to optimize methods to evaluate vaccine impact and effectiveness. He is deputy director of the International Vaccine Access Center at Johns Hopkins, which aims to accelerate equitable and sustainable access to vaccines in low- and middle-income countries by generating, synthesizing, and using evidence to inform decision making and action.

Naor is co-principal investigator on a Bill & Melinda Gates Foundation funded, WHO sponsored 7-country randomized clinical trial of azithromycin in childhood diarrhea, and co-investigator on a Gates Foundation funded randomized trial of a novel neonatal rotavirus vaccine together with colleagues at the Universities of Melbourne and Liverpool. He is undertaking typhoid cost of illness studies with colleagues at PATH, the Universities of Liverpool and of Malawi and the TyVAC Consortium, and has supported Typhoid vaccine impact evaluation led by Aga Khan University in Pakistan. He was a founding member of the "Immunizing Pregnant Women and Infants (IMPRINT) Network", funded by UK’s Global Challenges Research Fund (GCRF), and was a member of the PATH led Advancing Maternal Immunization (AMI) Collaboration. Naor has been clinical trial statistician with the WHO, is member of data safety monitoring board for international trials of childhood malnutrition interventions, and a Scientific Advisory Panel member for safety studies of COVID-19 vaccines in pregnancy. He is a sought after commentator on COVID-19 vaccine development, deployment and distribution.

Prior to joining Johns Hopkins Bloomberg School of Public Health, Dr Bar-Zeev led the Vaccines Research Group at the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi from 2011 to 2016, and was member of the Malawi National Immunization Technical Advisory Group. He established the Wellcome Trust funded multisite national vaccine surveillance program in Malawi (VacSurv), that included several case-control and large scale population cohort studies examining pneumococcal conjugate and rotavirus vaccine impact and effectiveness against disease and mortality as well as cost-effectiveness evaluations of vaccines in partnership with PATH. He also worked as pediatric infectious diseases specialist at Queen Elizabeth Central Hospital in Blantyre, Malawi, where he continues clinical practice on a visiting basis.

Dr Bar-Zeev is Fellow of the Royal Australasian College of Physicians, dual certified in general pediatrics and infectious diseases, Fellow of the Australasian College of Tropical Medicine, Fellow of the Royal Statistical Society (UK) and an Accredited Statistician with the Statistical Society of Australia. His PhD in epidemiology was undertaken at the Menzies School of Health Research, Charles Darwin University, in Darwin, northern Australia. Dr Bar-Zeev has over 20 years’ experience in global child health across East Asia, the Pacific and Africa, and has worked with the WHO, UNICEF and Save the Children. He has received funding from Gates Foundation, PATH, CDC, NIH and industry.

Conflict of interest declaration: Dr Bar-Zeev has initiated and obtained research grants from Glaxo-Smith-Kline Biologicals, Takeda Pharmaceuticals, Merck, the Serum Institute of India and Johnson & Johnson. He has not received personal payment or any other benefit from any pharmaceutical company, and has no financial interests in the vaccine industry.
Select Publications
Recent first author publications
  • Bar-Zeev N*, Swarthout TD*, Everett DB, Alaerts M, Msefula J, Brown C, Bilima S, Mallewa J, King C, von Gottberg A, Verani JR, Whitney CG, Mwansambo C, Gordon SB, Cunliffe NA, French N, Heyderman RS, for the VacSurv Consortium. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies. Lancet Glob Health 2021; 9: e989–98 (* joint first authors)
  • Bar-Zeev N*, King C*, Phiri T, Beard J, Mvula H, Crampin AC, Heinsbroek E, Lewycka S, Tate JE, Parashar UD, Costello A, Mwansambo C, Heyderman RS, French N, Cunliffe NA, for the VacSurv Consortium. Impact of monovalent rotavirus vaccine on diarrhoea-associated post-neonatal infant mortality in rural communities in Malawi: a population-based birth cohort study. Lancet Glob Health 2018; 6:e1036–44 (* joint first authors)
  • Bar-Zeev N, Kapanda L, Tate JE, Jere KC, Iturriza-Gomara M, Nakagomi O, Mwansambo C, Costello A, Parashar UD, Heyderman RS, French N, Cunliffe NA; VacSurv Consortium. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. Lancet Infect Dis. 2015 Apr;15(4):422-8
  • Bar-Zeev N, Inglesby T. COVID-19 vaccines: early success and remaining challenges. Lancet. 2020 Sep 26;396(10255):868-869.
  • Bar-Zeev N, Moss WJ. Encouraging results from phase 1/2 COVID-19 vaccine trials. Lancet. 2020 Aug 15;396(10249):448-449
Antibiotics in Childhood Diarrhea (ABCD) Trial
Optimizing Vaccine Schedules to Improve Child Health
Typhoid Cost of Illness
Baltimore City Influenza Vaccine Initiative Evaluation
COVID-19 Vaccine Effectiveness: global review